Areteia Therapeutics reported positive Phase 3 results for dexpramipexole, an oral small molecule targeting eosinophilic asthma. The Exhale-4 trial met its primary endpoint, showing significant lung function improvement and blood eosinophil count reduction. This success positions dexpramipexole as a potential oral alternative to injectable biologic therapies for asthma, highlighting the company’s strategy in repurposing ALS therapeutics. Additional Phase 3 studies are underway to support FDA submissions.